Ryan L. Powles

Bristol-Myers Squibb (Germany) — Germany

Medicine · Health Sciences

10h-index956citations38works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(18), Cancer Genomics and Diagnostics(11), BRCA gene mutations in cancer(5), Genetic Associations and Epidemiology(4), Neuroblastoma Research and Treatments(4)

Publications38 total

Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12C
Nature Communications·2026Open Access
Data from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S3 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S6 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S7 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Table S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S2 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S4 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S1 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Figure S5 from Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
2025Open Access
Discovery of BMS-986408, a First-In-Class Dual DGKα and DGKζ Inhibitor that Unleashes PD-1 Checkpoint and CAR T-cell Immunotherapies
Cancer Immunology Research·2025· 6 citedOpen Access
DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity
Science Translational Medicine·2023· 23 cited
Figure S2 from Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
2023Open Access
Figure S2 from Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
2023Open Access
Figure S3 from Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
2023Open Access
Figure S1 from Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Michael Wichroski(15), Joseph L. Benci(15), Si-Qi Liu(15), Louis Chupak(15), Joelle M. Onorato(15), Hongchen Qiu(15), Dana Banas(15), Gregory Locke(15), Abigail E. Witt(15), Huilin Qi(15), Yuka Amako(15), Tai Wang(15), Lauren M. Zasadil(14), Patrick C. Gedeon(14), Kendall J. Condon(14), Suhasini Joshi(14), Shana Posy(14), Patrick Carlson(14), Alison Maier(14), Jiao Shen(14)